Biosergen publishes interim report for fourth quarter 2023
Thursday, February 29, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the fourth quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q4 2023
| 2023 | 2022 | 2023 | 2022 | |
| TSEK | Oct-Dec | Oct-Dec | Jan-Dec | Jan-Dec |
| Other income | 1.315 | 1.964 | 9.378 | 5.183 |
| Profit/loss before depreciation (EBITDA) | -6.662 | -12.491 | -27.266 | -39.987 |
| Operating profit/loss befor net financials | -6.662 | -12.491 | -27.037 | -39.987 |
| Net financials | 193 | 87 | 229 | 109 |
| Netprofit/loss for the period | -6.469 | -12.432 | -27.037 | -39.906 |
| Earnings per share (SEK) | -0,13 | -0,40 | -0,53 | -1,28 |
Highlights during Q4 2023
- December 12, Biosergen’s Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy
Highlights after the period
- February 12, Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
- January 30, Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan
- January 12, Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor
The Financial report can be found on our website: https://biosergen.net/investors/filings
